Study: NCT04612751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Intravenous infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion Q3W on Day 1 or Day 2 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2936
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI5752
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7789
Description: Intravenous infusion prior to Dato-DXd every 3 weeks (Q3W) on Day 1 prior to Dato-Dxd of each 21-day cycle